Representatives from Novartis stood behind the safety and efficacy of Beovu, a treatment for wet age-related macular degeneration, after the American Society of Retina Specialists shared an update with its membership on possible side effects of the therapy.
The American Society of Retina Specialists (ASRS) only shared the update with its members, but according to a Novartis statement sent to Healio/OSN, the update discussed reports of 14 cases of vasculitis in patients treated with Beovu (brolucizumab-dbll) since the therapy’s FDA approval in October 2019.
The ASRS update noted 11 of the
Uncategorized